Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial

Highlights

The WAYFINDER trial provides critical evidence for the use of tezepelumab in reducing systemic steroid exposure in patients with severe asthma. Key findings include:

• Approximately 90% of patients achieved a maintenance oral corticosteroid (OCS) dose of 5 mg per day or less by week 52.
• Complete OCS discontinuation was achieved by 50.3% of participants at one year, representing a significant milestone in asthma management.
• Efficacy in OCS reduction was observed across all patient subgroups, independent of baseline blood eosinophil counts (BEC), fractional exhaled nitric oxide (FeNO), or allergy status.
• The safety profile remained consistent with previous tezepelumab trials, with no new safety signals identified despite the tapering of systemic steroids.